Sep 29, 2020 / 08:00PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Galectin Therapeutics conference call to discuss the initiation of the adaptive Phase 2b/3 belapectin clinical trial, the NASH-RX trial.
(Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the conference over to Mr. Jack Callicutt, CFO of Galectin Therapeutics.
Jack Callicutt - Galectin Therapeutics - CFO
Thank you, and good afternoon. I'm Jack Callicutt, Chief Financial Officer of Galectin Therapeutics, and I'd like to welcome you to our conference call to discuss our NASH-RX clinical trial.
Joining me this afternoon are Joel Lewis, CEO and President; Dr. Harold Shlevin, a member of our Board of Directors, currently a consultant to the company and our former CEO and President; and Dr. Pol Boudes, our Chief Medical Officer.
Before I turn the call over to Joel, I'd like to remind you that certain comments made during this conference call, particularly those anticipating our future financial condition and results of
Galectin Therapeutics Inc to Discuss NASH-RX Clinical Trial and Introduce New CEO Conference Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers